Alpha Cognition Inc. Common Stock
$6.89
▲
0.34%
2026-04-21 05:03:01
www.alphacognition.com
NCM: ACOG
Explore Alpha Cognition Inc. Common Stock stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$150.02 M
Current Price
$6.89
52W High / Low
$11.54 / $3.97
Stock P/E
—
Book Value
$2.88
Dividend Yield
—
ROCE
-23.03%
ROE
-40.68%
Face Value
—
EPS
$-1.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
2.52
Debt / Equity
0.02
Current Ratio
8.65
Quick Ratio
8.09
Forward P/E
-31.74
Price / Sales
12.85
Enterprise Value
$65.25 M
EV / EBITDA
-2.89
EV / Revenue
6.38
Rating
Strong Buy
Target Price
$18
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 2. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 3. | AN2 Therapeutics, Inc. | $3.62 | — | $129.78 M | — | -71.59% | -52.14% | $6.91 / $1 | $1.94 |
| 4. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
| 5. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 6. | Aptorum Group Limited | $0.9 | — | $7.21 M | — | -12.89% | -10.79% | $4.47 / $0.65 | $2.84 |
| 7. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.79 M | 2.84 M | 1.66 M | 2.93 M | 0 M | — |
| Operating Profit | -7.93 M | -5.3 M | -5.74 M | -3.61 M | -2.35 M | — |
| Net Profit | -6.86 M | -1.32 M | -10.49 M | -2.01 M | -5.66 M | — |
| EPS in Rs | -0.31 | -0.06 | -0.48 | -0.09 | -0.26 | -0.31 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 10.22 M | 0 M | 0 M | 0 M |
| Operating Profit | -22.58 M | -11.55 M | -9.62 M | -13.47 M |
| Net Profit | -20.67 M | -14.79 M | -13.76 M | -12.11 M |
| EPS in Rs | -0.95 | -0.68 | -0.63 | -0.56 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 79.73 M | 50.74 M | 2.45 M | 2.95 M |
| Total Liabilities | 17.2 M | 11.64 M | 7.16 M | 4.27 M |
| Equity | 62.53 M | 39.09 M | -4.7 M | -1.32 M |
| Current Assets | 79.01 M | 50.25 M | 1.92 M | 2.33 M |
| Current Liabilities | 9.13 M | 3.35 M | 2.62 M | 4.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -20.38 M | -7.76 M | -8.8 M | -9.24 M |
| Investing CF | -0.29 M | -0.03 M | 0 M | -0 M |
| Financing CF | 38.21 M | 54.85 M | 8.23 M | 0.02 M |
| Free CF | -20.67 M | -7.78 M | -8.8 M | -9.25 M |
| Capex | -0.29 M | -0.03 M | — | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -7.45% | -13.61% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.